CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced that the Company will present data from the ongoing Phase 2a study of its lead clinical development candidate, CRLX101, at the AACR 102nd Annual Meeting 2011, ongoing in Orlando, Florida.
